A REVIEW OF MUCORMYCOSIS FOR POST COVID-19 COMPLICATION
Authors/Creators
- 1. 1Arulmigu Kalasalingam College of Pharmacy, Krishnankovil, Virudhunagar- 626126, India. 2JKKMMRF's- Annai JKK Sampoorani Ammal College of Pharmacy B. Komarapalaym, Namakkal - 638 183. 3Paavai College of Pharmacy and Research, R. Puliyampatti, Namakkal- 637 018.
Description
The pandemic coronavirus disease (COVID-19) continues to be a giant downside worldwide. Severe coronavirus disease (COVID-19) is presently managed with general glucocorticoids that improves survival rate in COVID-19 patients. Sadly, the in depth use of glucocorticoids will cause secondary microorganism or fungal infections. Whereas COVID-19 associated pulmonic aspergillosis is progressively recognized than mucormycosis. Mucormycosis is associate uncommon however serious infection that screw up the course of severe COVID-19. Mucormycosis is also a critical invasive fungal infection that arises notably in diabetic patients with or while not different underlying conditions like medical specialty malignancies or the need for solid-organ transplantation. Rhino-orbito-cerebral involvement is that the first website of mucormycosis, however the scarcity of signs may even be a reason for delayed identification. Contemporaneous hormone medical care most likely heightens the danger of mucormycosis. A high index of distrust and aggressive management is needed to boost outcomes.
Files
210804.pdf
Files
(772.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8d95b8ac08b05c3ffe5fa549f1c396bd
|
772.5 kB | Preview Download |